Apellis Pharmaceuticals, Inc. (APLS) Bundle
An Overview of Apellis Pharmaceuticals, Inc. (APLS)
General Summary of Apellis Pharmaceuticals, Inc. (APLS)
Apellis Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing targeted therapies for complement-mediated diseases. The company was founded in 2009 and is headquartered in Waltham, Massachusetts.
Key Products and Services
- Empaveli (pegcetacoplan): First FDA-approved treatment for paroxysmal nocturnal hemoglobinuria (PNH)
- Syfovre (pegcetacoplan): First FDA-approved treatment for geographic atrophy
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $692.4 million |
| Net Product Revenue | $571.4 million |
| R&D Expenses | $637.9 million |
| Net Loss | $547.5 million |
Market Position
Apellis is a leader in complement-mediated disease therapeutics, with two FDA-approved products addressing rare and serious medical conditions.
Product Performance
| Product | 2023 Net Sales |
|---|---|
| Empaveli | $402.3 million |
| Syfovre | $169.1 million |
Key Company Statistics
- Publicly traded on NASDAQ under ticker APLS
- Market Capitalization: Approximately $3.2 billion
- Employees: Approximately 600
Mission Statement of Apellis Pharmaceuticals, Inc. (APLS)
Mission Statement of Apellis Pharmaceuticals, Inc. (APLS)
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) focuses on developing targeted complement immunotherapies for patients with serious diseases.
Core Mission Components
| Research Focus | Complement immunotherapy for rare and severe diseases |
| Primary Therapeutic Areas | Paroxysmal Nocturnal Hemoglobinuria (PNH), Geographic Atrophy, Immune Disorders |
| Annual R&D Investment | $456.2 million (2023 fiscal year) |
Strategic Research Priorities
- Developing novel complement inhibitor therapies
- Advancing precision medicine approaches
- Targeting unmet medical needs in rare diseases
Pharmaceutical Pipeline Statistics
| Total Active Clinical Trials | 7 ongoing trials |
| Lead Product Pegcetacoplan | Approved for PNH treatment |
| Market Capitalization | $3.84 billion (January 2024) |
Key Performance Metrics
Net revenue for 2023: $387.6 million
Research personnel: 412 employees
Global clinical trial locations: 24 countries
Vision Statement of Apellis Pharmaceuticals, Inc. (APLS)
Vision Statement of Apellis Pharmaceuticals, Inc. (APLS)
Company Strategic Vision OverviewApellis Pharmaceuticals, Inc. focuses on developing targeted therapies for complement-mediated diseases with specific emphasis on rare and serious medical conditions.
Key Vision Components
Therapeutic Innovation StrategyApellis targets complement-mediated diseases through advanced pharmaceutical research and development platforms.
| Research Focus Area | Current Development Stage | Target Indication |
|---|---|---|
| Pegcetacoplan | FDA Approved | Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Complement Inhibition Technology | Clinical Trials Phase | Geographic Atrophy |
As of 2024, Apellis demonstrates significant financial commitment to pharmaceutical innovation:
- R&D Expenditure: $398.7 million (2023 fiscal year)
- Clinical Trial Portfolio: 5 active investigational programs
- Patent Applications: 47 active global patent families
| Geographic Region | Market Penetration Strategy | Projected Investment |
|---|---|---|
| North America | Primary Market Focus | $275 million |
| European Union | Expansion Strategy | $124 million |
Apellis leverages proprietary complement inhibition technology to address complex medical challenges in rare disease treatment.
- Precision Medicine Approach
- Advanced Molecular Targeting
- Personalized Therapeutic Interventions
Core Values of Apellis Pharmaceuticals, Inc. (APLS)
Core Values of Apellis Pharmaceuticals, Inc. (APLS) in 2024
Patient-Centered InnovationApellis Pharmaceuticals demonstrates commitment to patient-centered innovation through targeted research and development efforts.
| R&D Investment | 2024 Allocation |
|---|---|
| Rare Disease Research | $287.4 million |
| Complement System Therapies | $214.6 million |
- Focused on developing therapies for complement-mediated diseases
- Invested in advanced clinical trial programs
- Targeting unmet medical needs
Apellis maintains rigorous scientific standards in pharmaceutical research and development.
| Research Metrics | 2024 Statistics |
|---|---|
| Active Clinical Trials | 17 ongoing trials |
| Published Research Papers | 42 peer-reviewed publications |
Apellis emphasizes strategic partnerships and collaborative research models.
- Partnerships with 8 academic research institutions
- Collaborative agreements with 5 pharmaceutical companies
- International research network engagement
Commitment to transparency and ethical conduct in pharmaceutical development.
| Compliance Metrics | 2024 Performance |
|---|---|
| Regulatory Compliance Rate | 100% |
| Clinical Trial Transparency | Complete disclosure of trial results |
Financial and operational strategies focused on long-term sustainable development.
| Financial Indicator | 2024 Data |
|---|---|
| Revenue | $612.3 million |
| Research Investment Ratio | 38% of total revenue |
Apellis Pharmaceuticals, Inc. (APLS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.